See more : LadRx Corporation (LADX) Income Statement Analysis – Financial Results
Complete financial analysis of Fresh Tracks Therapeutics, Inc. (FRTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Fresh Tracks Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hochschild Mining plc (HCHDY) Income Statement Analysis – Financial Results
- Imagenetix, Inc. (IAGX) Income Statement Analysis – Financial Results
- The Ruby Mills Limited (RUBYMILLS.BO) Income Statement Analysis – Financial Results
- Chamni’s Eye Public Company Limited (CEYE.BK) Income Statement Analysis – Financial Results
- Inovio Pharmaceuticals, Inc. (GBMB.F) Income Statement Analysis – Financial Results
Fresh Tracks Therapeutics, Inc. (FRTX)
About Fresh Tracks Therapeutics, Inc.
Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.01M | 6.94M | 404.00K | 1.82M | 7.92M | 1.62M | 13.82M | 14.53M | 20.95M | 15.22M | 7.72M | 17.52M | 30.02M | 8.71M | 12.69M | 7.96M | 5.51M | 14.74M | 12.00M | 14.55M | 8.08M | 7.01M | 11.37M | 7.62M | 10.70M | 5.90M | 7.80M | 6.70M | 6.30M | 5.50M | 6.00M | 3.60M | 2.40M | 1.80M |
| Cost of Revenue | 0.00 | 14.04M | 28.23M | 11.22M | 20.21M | 1.44M | 6.48M | 6.29M | 10.93M | 10.82M | 12.70M | 0.00 | 10.27M | 11.44M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.20M | -1.00M | -900.00K | -900.00K | -600.00K | -500.00K | -500.00K | 5.70M | 4.00M | 3.00M | 2.20M |
| Gross Profit | 8.01M | -7.10M | -27.83M | -9.39M | -12.30M | 186.00K | 7.34M | 8.24M | 10.02M | 4.39M | -4.98M | 17.52M | 19.75M | -2.73M | 12.69M | 7.96M | 5.51M | 14.74M | 12.00M | 14.55M | 8.08M | 7.01M | 11.37M | 8.82M | 11.70M | 6.80M | 8.70M | 7.30M | 6.80M | 6.00M | 300.00K | -400.00K | -600.00K | -400.00K |
| Gross Profit Ratio | 100.00% | -102.26% | -6,887.87% | -515.59% | -155.32% | 11.47% | 53.12% | 56.71% | 47.84% | 28.87% | -64.52% | 100.00% | 65.80% | -31.28% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 115.75% | 109.35% | 115.25% | 111.54% | 108.96% | 107.94% | 109.09% | 5.00% | -11.11% | -25.00% | -22.22% |
| Research & Development | 3.18M | 14.04M | 28.23M | 11.22M | 20.21M | 12.33M | 14.39M | 10.36M | 11.06M | 11.47M | 14.56M | 17.34M | 17.98M | 19.69M | 23.45M | 25.53M | 22.93M | 18.51M | 17.77M | 31.18M | 26.78M | 26.37M | 22.07M | 18.51M | 15.30M | 12.10M | 11.90M | 11.30M | 9.00M | 8.30M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 11.18M | 14.43M | 12.42M | 11.58M | 12.17M | 8.94M | 12.81M | 13.35M | 19.29M | 20.38M | 24.51M | 23.61M | 0.00 | 8.80M | 7.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.44M | 6.48M | 6.29M | 10.93M | 10.82M | 12.70M | 13.06M | 0.00 | 0.00 | 10.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.18M | 14.43M | 12.42M | 11.58M | 12.17M | 8.94M | 12.81M | 13.35M | 19.29M | 20.38M | 24.51M | 23.61M | 9.60M | 8.80M | 17.82M | 19.77M | 22.84M | 22.64M | 19.88M | 8.51M | 6.92M | 8.06M | 6.52M | 5.27M | 4.40M | 3.60M | 3.70M | 3.20M | 2.90M | 2.60M | 2.00M | 1.40M | 1.10M | 800.00K |
| Other Expenses | 0.00 | 441.00K | 839.00K | 0.00 | 0.00 | -1.44M | -6.48M | -6.29M | -10.93M | -10.82M | -12.70M | -13.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 482.22K | 4.20M | 0.00 | 1.20M | 1.00M | 900.00K | 900.00K | 600.00K | 500.00K | 500.00K | 400.00K | 400.00K | 600.00K | 600.00K |
| Operating Expenses | 14.37M | 28.48M | 40.65M | 22.80M | 32.39M | 21.27M | 27.21M | 23.71M | 30.35M | 31.84M | 39.07M | 40.95M | 27.57M | 28.49M | 41.27M | 45.30M | 45.77M | 41.16M | 37.65M | 39.69M | 34.18M | 38.64M | 28.60M | 24.98M | 20.70M | 16.60M | 16.50M | 15.10M | 12.40M | 11.40M | 2.40M | 1.80M | 1.70M | 1.40M |
| Cost & Expenses | 14.37M | 28.48M | 40.65M | 22.80M | 32.39M | 21.27M | 27.21M | 23.71M | 30.35M | 31.84M | 39.07M | 40.95M | 37.84M | 39.93M | 41.27M | 45.30M | 45.77M | 41.16M | 37.65M | 39.69M | 34.18M | 38.64M | 28.60M | 23.78M | 19.70M | 15.70M | 15.60M | 14.50M | 11.90M | 10.90M | 8.10M | 5.80M | 4.70M | 3.60M |
| Interest Income | 0.00 | 9.00K | 69.00K | 63.00K | 1.94M | 61.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.83M | 2.21M | 2.07M | 3.98M | 8.29M | 9.36M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 5.00K | 9.00K | 69.00K | 0.00 | 2.10M | 1.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00K | 21.00K | 96.00K | 272.00K | 533.00K | 795.00K | 412.82K | 288.25K | 296.58K | 204.60K | 0.00 | 200.00K | 0.00 | 100.00K | 100.00K | 100.00K | 100.00K | 0.00 | 100.00K | 100.00K |
| Depreciation & Amortization | 41.00K | 30.00K | 22.00K | 10.00K | 28.00K | 49.00K | 793.00K | 1.12M | 1.16M | 1.66M | 2.21M | 1.98M | 2.30M | 2.81M | 2.63M | 2.87M | 3.26M | 3.28M | 3.59M | 3.64M | 3.54M | 2.74M | 1.88M | 1.20M | 1.00M | 900.00K | 900.00K | 600.00K | 500.00K | 500.00K | 400.00K | 400.00K | 600.00K | 600.00K |
| EBITDA | -5.65M | -21.06M | -39.38M | -20.90M | -24.47M | -19.50M | -12.59M | -8.06M | -8.25M | -14.96M | -29.14M | -21.11M | -5.32M | -28.41M | -25.93M | -34.48M | -37.00M | -23.13M | -22.06M | -21.51M | -22.56M | -28.89M | -15.35M | -14.96M | -8.00M | -8.90M | -6.90M | -7.20M | -5.10M | -4.90M | -1.70M | -1.80M | -1.70M | -1.20M |
| EBITDA Ratio | -70.55% | -303.80% | -9,961.39% | -1,151.26% | -309.06% | -1,420.35% | -99.95% | -64.56% | -40.15% | -110.14% | -407.70% | -136.81% | -27.85% | -326.10% | -204.85% | -439.20% | -752.21% | -180.97% | -183.76% | -147.86% | -273.30% | -352.37% | -135.02% | -196.31% | -74.77% | -191.53% | -119.23% | -149.25% | -107.94% | -110.91% | -43.33% | -58.33% | -75.00% | -77.78% |
| Operating Income | -6.36M | -21.53M | -40.24M | -20.98M | -24.47M | -19.65M | -13.39M | -9.18M | -9.40M | -16.63M | -31.35M | -23.43M | -7.82M | -31.22M | -28.59M | -37.34M | -40.26M | -26.42M | -25.65M | -25.14M | -26.10M | -31.63M | -17.23M | -16.16M | -9.00M | -9.80M | -7.80M | -7.80M | -5.60M | -5.40M | -2.10M | -2.20M | -2.30M | -1.80M |
| Operating Income Ratio | -79.44% | -310.15% | -9,961.39% | -1,151.26% | -309.06% | -1,211.22% | -96.87% | -63.15% | -44.89% | -109.26% | -406.22% | -133.76% | -26.06% | -358.34% | -225.34% | -469.37% | -730.44% | -179.22% | -213.70% | -172.86% | -323.12% | -451.36% | -151.59% | -212.06% | -84.11% | -166.10% | -100.00% | -116.42% | -88.89% | -98.18% | -35.00% | -61.11% | -95.83% | -100.00% |
| Total Other Income/Expenses | 666.00K | 432.00K | 770.00K | 63.00K | 591.00K | 3.39M | 426.00K | 204.00K | 166.00K | 134.00K | 114.00K | 534.00K | 539.00K | 830.00K | 28.00K | 468.00K | 4.46M | 3.54M | 0.00 | 0.00 | -481.56K | -4.20M | 0.00 | 0.00 | 0.00 | 2.40M | 2.40M | 2.80M | 1.70M | 1.20M | 900.00K | 300.00K | 100.00K | 200.00K |
| Income Before Tax | -5.69M | -21.10M | -39.47M | -20.91M | -23.88M | -16.25M | -12.96M | -8.97M | -9.24M | -16.49M | -31.24M | -22.90M | -7.28M | -30.39M | -28.56M | -36.88M | -35.80M | -22.88M | 0.00 | 0.00 | -26.59M | -35.83M | 0.00 | 0.00 | 0.00 | -7.40M | -5.40M | -5.00M | -3.90M | -4.20M | -1.20M | -1.90M | -2.20M | -1.60M |
| Income Before Tax Ratio | -71.12% | -303.93% | -9,770.79% | -1,147.80% | -301.59% | -1,002.10% | -93.78% | -61.75% | -44.10% | -108.38% | -404.74% | -130.71% | -24.26% | -348.81% | -225.10% | -463.49% | -649.46% | -155.20% | 0.00% | 0.00% | -329.09% | -511.30% | 0.00% | 0.00% | 0.00% | -125.42% | -69.23% | -74.63% | -61.90% | -76.36% | -20.00% | -52.78% | -91.67% | -88.89% |
| Income Tax Expense | 0.00 | -441.00K | 47.00K | -10.00K | 2.07M | 4.48M | -1.22M | -1.32M | -166.00K | -1.80M | -2.33M | -2.52M | -2.84M | 0.00 | -28.00K | -447.00K | -4.37M | -3.27M | -1.29M | -1.41M | -1.65M | -3.70M | -7.99M | -7.64M | -2.10M | -2.30M | -2.20M | -2.70M | -1.60M | -1.00M | -700.00K | -200.00K | 0.00 | -100.00K |
| Net Income | -5.69M | -20.66M | -39.52M | -20.90M | -25.95M | -16.25M | -12.96M | -8.97M | -9.24M | -16.49M | -31.24M | -22.90M | -7.28M | -30.39M | -28.56M | -36.90M | -35.89M | -23.15M | -24.36M | -23.73M | -24.45M | -27.93M | -9.24M | -8.52M | -6.90M | -7.50M | -5.60M | -5.10M | -4.00M | -4.40M | -1.40M | -2.00M | -2.30M | -1.70M |
| Net Income Ratio | -71.12% | -297.58% | -9,782.43% | -1,147.26% | -327.71% | -1,002.10% | -93.78% | -61.75% | -44.10% | -108.38% | -404.74% | -130.71% | -24.26% | -348.81% | -225.11% | -463.75% | -651.20% | -157.04% | -202.92% | -163.17% | -302.65% | -398.62% | -81.29% | -111.77% | -64.49% | -127.12% | -71.79% | -76.12% | -63.49% | -80.00% | -23.33% | -55.56% | -95.83% | -94.44% |
| EPS | -0.96 | -7.36 | -22.14 | -38.37 | -386.21 | -234.41 | -316.76 | -282.12 | -317.17 | -585.11 | -1.13K | -839.10 | -318.51 | -1.59K | -1.91K | -2.92K | -2.89K | -2.32K | -3.12K | -3.29K | -3.83K | -4.38K | -1.45K | -1.36K | -1.35K | -1.50K | -1.14K | -1.04K | -913.45 | -1.07K | -440.94 | -724.38 | -850.59 | -693.03 |
| EPS Diluted | -0.96 | -7.36 | -22.14 | -38.37 | -386.21 | -234.41 | -316.76 | -282.12 | -317.17 | -585.11 | -1.13K | -839.10 | -318.51 | -1.59K | -1.91K | -2.92K | -2.89K | -2.32K | -3.12K | -3.29K | -3.83K | -4.38K | -1.45K | -1.36K | -1.35K | -1.49K | -1.14K | -1.04K | -913.45 | -1.07K | -440.94 | -724.38 | -850.59 | -693.03 |
| Weighted Avg Shares Out | 5.91M | 2.81M | 1.78M | 544.76K | 67.18K | 69.34K | 40.91K | 31.81K | 29.13K | 28.19K | 27.57K | 27.29K | 22.87K | 19.07K | 14.95K | 12.65K | 12.44K | 9.98K | 7.80K | 7.20K | 6.38K | 6.37K | 6.36K | 6.25K | 5.12K | 5.02K | 4.92K | 4.88K | 4.38K | 4.11K | 3.18K | 2.76K | 2.70K | 2.45K |
| Weighted Avg Shares Out (Dil) | 5.91M | 2.81M | 1.78M | 544.76K | 67.18K | 69.34K | 40.91K | 31.81K | 29.13K | 28.19K | 27.57K | 27.29K | 22.87K | 19.07K | 14.95K | 12.65K | 12.44K | 9.98K | 7.80K | 7.20K | 6.38K | 6.37K | 6.36K | 6.25K | 5.12K | 5.04K | 4.93K | 4.89K | 4.38K | 4.11K | 3.18K | 2.76K | 2.70K | 2.45K |
Avacta Group appoints BBI Solutions as manufacturing partner for rapid SARS-CoV-2 antigen test - DirectorsTalk
Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has announced that it has appointed BBI Solutions, part of BBI Group, to manufacture the saliva-based rapid SARS-CoV-2 antigen test that is being developed with Cytiva. BBI Solutions is a...
Avacta Appoints COVID-19 Rapid Antigen Test Manufacturing Partner
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has appointed BBI Solutions, part
BBI support scored at 47 per cent in new survey
NAIROBI, Kenya, Jul 22 – A new study by Research firm Intel Research Solutions (IRS) has projected the popularity of the Building Bridges Initiative (BBI) spearheaded by President Uhuru Kenyatta and Raila Odinga at 47 per cent. The survey published on Wednesday...
Amazon CEO Jeff Bezos adds record $13 billion to his fortune in single day
Jeff Bezos’s net worth swelled a mammoth $74.4 billion in 2020 and his total fortune is now worth $189 billion. This despite the major economic depression caused by the coronavirus pandemic.
The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Altimmune Inc (NASDAQ: ALT...
The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Akero Therapeutics Inc (...
Broadband Infraco adds capability to monitor WACS
Analysts laud the state-owned entity’s decision to add undersea cable monitoring as part of its new service offerings.
The Daily Biotech Pulse: T2 Biosystems Launches COVID-19 Test, Akero Aces Midstage NASH Study, Aravive Added to Russell Indexes
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) ADC Therapeutics SA (NYSE:...
BBI team ready to present final report
NAIROBI, Kenya Jun 30 – The Building Bridges Initiative Steering Committee says it has completed its task, and is now ready to present its final report. Joint Secretaries of the Taskforce, Martin Kimani and Paul Mwangi, said they have already...
Source: https://incomestatements.info
Category: Stock Reports